Key figures

Second quarter, April 1 – June 30, Q2 2025

(figures in parentheses refer to the corresponding period in the previous year)

  • Net sales amounted to 0 (0).
  • Other operating income amounted to 946 (18) thousand SEK.
  • Profit after tax amounted to -12,740 (-11,224) thousand SEK.
  • Earnings per share before and after dilution: -0.02 (-0.02) SEK.
  • Cash flow from operating activities was -4,699 (-88) thousand SEK.

 

First half of the year, January 1 – June 30, 2025

  • Net sales amounted to 0 (0).
  • Other operating income amounted to 2,608 (86) thousand SEK.
  • The profit after tax amounted to –23,676 (-20,152) thousand SEK.
  • Earnings per share before and after dilution: -0.03 (-0.04) SEK.
  • Cash flow from operating activities was -13,875 (-8,888) thousand SEK.

 

Significant events during the quarter

  • Study demonstrated rapid biomarker integration on Psyros™ POC platform
    A joint research project between Prolight and cardiologist Dr. Sam McGrath at St Thomas’ Hospital demonstrated how quickly a test for the cardiac biomarker cMyC can be transferred to the Psyros POC system. The study highlighted the platform’s potential and its broader diagnostic applications beyond high-sensitivity troponin.
  • Prolight granted its first two European patents for Psyros technology
    The company’s first two European patents for Psyros technology for single-molecule counting
    were granted by the European Patent Office (EPO). The patents are valid until 2040 and 2041,
    respectively.
  • Prolight granted new MicroFlex patent in the U.S. The U.S. Patent and Trademark Office approved Prolight’s patent for the analytical unit and reaction chamber of its MicroFlex point-of-care diagnostic system.
  • Prolight resolved on a rights issue
    At an extraordinary general meeting on June 10, 2025, Prolight resolved to carry out a rights issue of SEK 100.3 million. The subscription period ran from June 16 to June 30, 2025. The proceeds are intended to complete the development of the Psyros system.
  • New chairman of the board
    Fredrik Alpsten was elected as a new board member and Chairman of the Board at the Annual General Meeting on June 30, 2025.
  • Prolight announced positive data from patient blood study at St Thomas’ Hospital, London Initial data from St Thomas’ Hospital confirmed the equivalence between whole blood and plasma in patients with elevated troponin levels. The study is an important step between the successful biobank study earlier this year and the planned regulatory clinical performance study.

 

Significant events after the end of the period

  • Prolight’s rights issue fully subscribed
    The rights issue was fully subscribed, with approximately 70.2 percent subscribed with subscription rights and about 29.8 percent without subscription rights. The net proceeds from the issue amount to approximately SEK 100.3 million before issuance costs and offsets. The new shares are now registered with the Swedish Companies Registration Office and delivered to the respective investors.
  • Prolight received patent approval in Japan for core Psyros patent Prolight Diagnostics was granted a patent for its Psyros single-molecule counting technology in Japan from the Japan Patent Office (JPO). The patent is valid until 2040.
  • Prolight showcased Psyros at ADLM 2025 in Chicago
    Prolight showcased for the first time a fully functioning commercial prototype of its groundbreaking point-of-care system, Psyros at the international congress Association for Diagnostics & Laboratory Medicine (ADLM) 2025, held in Chicago from July 27–29.
  • Prolight receives Notice of Intention to Grant in Europe for third Psyros patent
    The European Patent Office (EPO) has issued a Notice of Intention to Grant for the company’s third patent application related to its proprietary Psyros single-molecule-counting technology.

Subscribe